This combined therapy successfully reduced the lung metastasis rate of breast cancer patients by 84% by increasing the expression of cyt c and simultaneously reducing the expression of Bcl-2, matrix metalloproteinase-9 (MMP-9), and vascular endothelial growth factor(VEGF) [69]. Here, BCL2 is linked to breast carcinoma.